论文部分内容阅读
Background: XQ (Carfree, Nanjing, China), a new chemical entity that possesses pharmacological activity on PlateletActivating Factor (PAF).XQ was approved into phase Ⅰ evaluation for treatment of ischemic stroke in China.A nonlinear red blood cell (RBC,) binding/partition was observed in clinical trial within PUMCH, however in vitro assay result indicates that the blood to plasma (B/P) ratio of XQ is concentration time independent.